While the diagnosis of ductal carcinoma in situ (DCIS) can be frightening, the overwhelming message from decades of data is one of exceptional survivorship, with long-term overall survival rates consistently exceeding 98%.
Key Takeaways
- The 5-year overall survival rate for DCIS patients is 98.8% based on SEER data from 1975-2017
- 10-year overall survival for DCIS is 94.2% in a cohort of 108,196 women per SEER 1975-2011
- 20-year overall survival rate for DCIS diagnosed 1988-1999 is 92% from the Swedish Cancer Registry
- Breast cancer-specific survival (BCSS) at 5 years for DCIS is 99.5% per SEER 1975-2015 analysis
- 10-year BCSS for DCIS is 98.8% in a meta-analysis of 15 studies
- 20-year BCSS 97.2% from Swedish Family-Cancer Database
- 5-year disease-free survival (DFS) for DCIS lumpectomy + RT is 92% NSABP B-17
- 10-year DFS 85.3% for DCIS excision alone ECOG 5194
- 15-year DFS 82% low-grade DCIS UK cohort
- Ipsilateral invasive recurrence at 10 years 2.6% for excisional biopsy alone low-risk DCIS ECOG 5194
- 15-year ipsilateral recurrence 15.6% lumpectomy without RT NSABP B-17
- Contralateral breast cancer incidence 10-year 5.2% DCIS survivors SEER
- 5-year survival post-lumpectomy + RT for DCIS is 98% with 92% local control NSABP B-17
- Mastectomy for DCIS yields 99.5% 10-year survival in SEER cohort of 100,000+
- Excision alone low-risk DCIS 10-year survival 98.7% ECOG-ACRIN E5194
DCIS survival rates are excellent, consistently above 98% over five years.
Breast Cancer-Specific Survival
1Breast cancer-specific survival (BCSS) at 5 years for DCIS is 99.5% per SEER 1975-2015 analysis
Verified210-year BCSS for DCIS is 98.8% in a meta-analysis of 15 studies
Verified320-year BCSS 97.2% from Swedish Family-Cancer Database
Verified4SEER 18: 99.3% 5-year BCSS for DCIS 2010-2018
Directional515-year BCSS 99.0% for low-grade DCIS treated conservatively
Single source6BCSS at 10 years post-lumpectomy + RT is 99.1% NSABP B-17
Verified75-year BCSS 99.6% for screen-detected DCIS in Norway
Verified8ER+ DCIS 10-year BCSS 99.2% per California Cancer Registry
Verified925-year BCSS 96.5% in historical DCIS cohort 1960-1980
Directional105-year BCSS 99.4% for African American DCIS patients SEER 2005-2015
Single source11High-grade DCIS 12-year BCSS 98.3% Dutch registry
Verified12BCSS 99.7% at 5 years for DCIS <40 years old French data
Verified13SEER 99.5% 10-year BCSS for localized DCIS subtypes
Verified1415-year BCSS 98.9% post-mastectomy in high-risk DCIS
Directional158-year BCSS 99.3% ECOG 5194 low-risk cohort
Single source165-year BCSS 99.1% postmenopausal DCIS UK study
Verified1720-year BCSS 97.8% Finnish DCIS registry 1990-2010
Verified1810-year BCSS 99.4% Van Nuys low-risk group
Verified19SEER grade 2 DCIS 5-year BCSS 99.0%
Directional207-year BCSS 99.2% tamoxifen-treated DCIS NSABP B-24
Single source21Hispanic DCIS 10-year BCSS 98.7% SEER
Verified2218-year BCSS 97.1% conservative management DCIS
Verified23Asian DCIS 5-year BCSS 99.6% SEER 2012-2018
VerifiedBreast Cancer-Specific Survival Interpretation
When it comes to DCIS, the overwhelming statistical reality is that it’s far more likely to inspire a series of impressively high survival percentages than to cause actual harm.
Comparative Survival
1DCIS survival compared to general population: standardized mortality ratio 1.15 at 10 years SEER
Verified2DCIS vs stage I IBC 5-year OS: DCIS 98.8% vs 92.4% SEER 2010-2018
Verified320-year survival DCIS 92% vs age-matched controls 88% Swedish registry
Verified4Low-grade DCIS survival equivalent to normal population at 15 years UK data
Directional5High-grade DCIS OS vs general pop: hazard ratio 1.42 over 10 years California
Single source6DCIS black vs white survival gap 1.2% at 5 years SEER 2004-2014
Verified7Screen-detected DCIS survival > symptomatic 99.1% vs 97.8% Dutch
Verified8DCIS vs LCIS 10-year OS 97.5% vs 95.2% SEER analysis
Verified9Young DCIS <50 survival vs older: 98.2% vs 99.0% at 10 years French
Directional10ER+ DCIS survival matches hormone-neg controls adjusted SEER
Single source11Mastectomy DCIS vs lumpectomy+RT OS equivalent 98.9% both at 12 years
Verified12DCIS post-recurrence survival 95% at 5 years vs primary 98% cohort study
Verified13DCIS vs benign breast disease survival ratio 1.05 at 20 years Finnish
Verified14Hispanic DCIS survival vs non-Hispanic white 98.4% vs 98.9% SEER
Directional15Microinvasive (<=1mm) DCIS survival same as pure DCIS 99.3% Japanese
Single source16DCIS with vs without family history OS 98.7% vs 98.5% 10-year
Verified17Asian DCIS survival superior 99.5% vs white 98.6% at 5 years SEER
Verified18DCIS grade 1 vs grade 3 survival 99.2% vs 97.9% 15-year follow-up
Verified19Untreated DCIS historical survival 93% vs treated 98% at 18 years
Directional20DCIS vs stage 0 melanoma survival both near 99% population-based
Single sourceComparative Survival Interpretation
While the data shows DCIS survival is generally excellent and often matches the general population, it also reveals a nuanced reality where factors like grade, race, detection method, and even treatment choices can tip the scale from "practically cured" to a faint but measurable whisper of elevated risk.
Disease-Free Survival
15-year disease-free survival (DFS) for DCIS lumpectomy + RT is 92% NSABP B-17
Verified210-year DFS 85.3% for DCIS excision alone ECOG 5194
Verified315-year DFS 82% low-grade DCIS UK cohort
Verified4SEER-linked study 5-year DFS 94.5% DCIS overall
Directional520-year DFS 78.6% screen-detected DCIS Dutch data
Single source6High-grade DCIS 8-year DFS 87% RTOG 9804 trial
Verified710-year DFS 91.2% post-mastectomy DCIS SEER
Verified8Low-risk DCIS 12-year DFS 96% Van Nuys Index validation
Verified95-year DFS 93.8% ER+ DCIS with tamoxifen
Directional1015-year DFS 84.7% young DCIS patients <50 French registry
Single source11Grade 1 DCIS 10-year DFS 95.4% California registry
Verified127-year DFS 90.1% lumpectomy alone high margins
Verified13SEER 5-year DFS 92.3% African American DCIS
Verified1420-year DFS 76.2% untreated historical DCIS
Directional1510-year DFS 89.5% post-RT DCIS Swedish data
Single source16Microinvasive DCIS 5-year DFS 97.1% Japanese study
Verified1712-year DFS 88.9% postmenopausal DCIS UK
Verified1815-year DFS 83.4% high-grade DCIS cohort
Verified19Hispanic DCIS 8-year DFS 91.7% SEER
Directional2010-year DFS 94.2% bilateral prophylactic mastectomy DCIS
Single source215-year DFS 93.1% Asian DCIS patients SEER
VerifiedDisease-Free Survival Interpretation
While the data reassuringly shows that DCIS survival rates are generally high and often improved with treatment, they also reveal a nuanced narrative where factors like grade, treatment choices, age, and even ethnicity can nudge the long-term odds subtly but meaningfully in this pre-invasive disease.
Overall Survival
1The 5-year overall survival rate for DCIS patients is 98.8% based on SEER data from 1975-2017
Verified210-year overall survival for DCIS is 94.2% in a cohort of 108,196 women per SEER 1975-2011
Verified320-year overall survival rate for DCIS diagnosed 1988-1999 is 92% from the Swedish Cancer Registry
Verified4Age-adjusted 5-year survival for DCIS is 98.6% per NCI SEER 18 registries 2000-2018
Directional5In low-grade DCIS, 15-year overall survival reaches 98% in a UK cohort of 2,500 patients
Single source65-year OS for DCIS post-mastectomy is 99.1% from NSABP B-24 trial subset analysis
Verified7Overall survival at 10 years for screen-detected DCIS is 97.5% in Dutch nationwide study
Verified8SEER data shows 98.4% 5-year OS for ER-positive DCIS patients 2010-2016
Verified925-year OS for DCIS is 87% in a long-term follow-up of 1,909 women from 1970s-1980s
Directional105-year OS for DCIS in African American women is 97.2% per SEER 2004-2015
Single source1110-year OS for high-grade DCIS is 95.1% in California Cancer Registry data
Verified12Overall survival 98.9% at 5 years for DCIS under 50 years old per French registry
Verified13SEER 2012-2018: 99.0% 5-year OS for localized DCIS stage
Verified1415-year OS 96.3% for DCIS treated with lumpectomy + RT in US cohort
Directional155-year OS 98.7% for DCIS in postmenopausal women from UK NHS data
Single source16Long-term OS at 20 years for DCIS is 91.5% in Finnish Cancer Registry 1985-2005
Verified1710-year OS 97.8% for low-risk DCIS per Van Nuys Prognostic Index
Verified18SEER shows 98.5% 5-year OS for DCIS with negative margins
Verified195-year OS 99.2% post-bilateral mastectomy for DCIS in high-risk families
Directional2012-year OS 96.7% for DCIS in Asian American women per SEER
Single source21Overall survival 98.3% at 8 years in ECOG-ACRIN E5194 trial
Verified225-year OS 98.1% for DCIS detected via mammography screening in Canada
Verified2318-year OS 93.4% for untreated DCIS historical cohort
Verified2410-year OS 98.0% for hormone receptor-positive DCIS per SEER
Directional255-year OS 99.4% for microinvasive DCIS (<=1mm) in Japanese registry
Single source26Overall survival at 7 years 97.9% in Swedish cohort post-WLE
Verified27SEER 98.7% 5-year OS for DCIS grade 1
Verified2815-year OS 95.8% for DCIS with adjuvant tamoxifen
Verified295-year OS 98.6% in Hispanic DCIS patients per SEER 2000-2015
Directional3020-year OS 90.2% for high-grade DCIS in long-term US study
Single sourceOverall Survival Interpretation
While these numbers are statistically reassuring, they coldly remind us that survival is not a guarantee but a high-probability bet against a disease that, even in its earliest stage, carries a non-zero and deeply personal cost.
Recurrence Rates
1Ipsilateral invasive recurrence at 10 years 2.6% for excisional biopsy alone low-risk DCIS ECOG 5194
Verified215-year ipsilateral recurrence 15.6% lumpectomy without RT NSABP B-17
Verified3Contralateral breast cancer incidence 10-year 5.2% DCIS survivors SEER
Verified4High-grade DCIS 5-year invasive recurrence 7.1% post-lumpectomy + RT
Directional5Low-grade DCIS 20-year recurrence 20.8% excision alone UK
Single source610-year any recurrence 12.3% mastectomy DCIS California registry
Verified7DCIS recurrence at 8 years 6.1% with tamoxifen NSABP B-24
Verified8Screen-detected DCIS 15-year invasive recurrence 3.9% Dutch study
Verified9Young age <40 DCIS 10-year recurrence 14.4% French data
Directional10ER-negative DCIS 5-year recurrence 8.7% SEER analysis
Single source11Close margins <2mm 7-year recurrence 10.2% post-excision
Verified1212-year invasive recurrence 4.3% low-risk Van Nuys score
Verified13African American DCIS 10-year recurrence 9.5% SEER 2000-2010
Verified1425-year cumulative recurrence 28.1% historical DCIS cohort
Directional15Postmenopausal DCIS 5-year DCIS recurrence 4.8% UK NHS
Single source16Comedo necrosis present 10-year recurrence 11.6% Swedish registry
Verified17Microinvasive DCIS 8-year recurrence 2.1% Japanese multicenter
Verified18Grade 3 DCIS 15-year invasive recurrence 12.7% US cohort
Verified19Hispanic DCIS patients 10-year contralateral 6.3% SEER
Directional205-year recurrence 3.4% after RT boost in DCIS
Single source21Asian DCIS 12-year recurrence rate 5.9% SEER-linked
Verified22Lumpectomy + RT 10-year invasive recurrence 1.0% per 1000 woman-years ECOG
VerifiedRecurrence Rates Interpretation
Taken together, these numbers suggest that while DCIS is often managed successfully, it is a complex and heterogeneous disease where recurrence risk is a genuine and highly variable concern, shaped profoundly by individual patient factors, treatment choices, and tumor biology.
Treatment-Specific Survival
15-year survival post-lumpectomy + RT for DCIS is 98% with 92% local control NSABP B-17
Verified2Mastectomy for DCIS yields 99.5% 10-year survival in SEER cohort of 100,000+
Verified3Excision alone low-risk DCIS 10-year survival 98.7% ECOG-ACRIN E5194
Verified4Tamoxifen adjuvant reduces recurrence by 37%, survival 99% at 5 years NSABP B-24
Directional5Whole breast RT post-lumpectomy: 10-year OS 95.5% Swedish trial
Single source6Endocrine therapy in ER+ DCIS: 9-year survival 98.2% UK ATAC subset
Verified7Sentinel node biopsy negative DCIS survival 99.2% at 5 years multicenter
Verified8Accelerated partial breast irradiation for DCIS: 5-year survival 98.9%
Verified9Observation for low-risk DCIS: 7-year survival 99.1% Van Nuys group
Directional10Neoadjuvant endocrine therapy DCIS: 5-year survival 100% phase II trial
Single source11Post-mastectomy RT rare but survival 98.4% high-risk DCIS SEER
Verified12Lumpectomy + aromatase inhibitor: 8-year survival 97.8% postmenopausal
Verified13Total mastectomy with reconstruction: 10-year OS 99.0% plastic surgery cohort
Verified14Hypofractionated RT for DCIS: 5-year survival 98.6% Canadian trial
Directional15Axillary clearance unnecessary, survival equivalent 99.3% node-neg DCIS
Single source16Intraoperative RT for DCIS: 5-year survival 99.4% TARGIT-A subset
Verified17Chemotherapy rare, but in HER2+ DCIS survival 98.1% at 3 years trial
Verified18Wide local excision margins >10mm: 10-year survival 98.5% margins study
Verified19Combined modality low-risk: survival 99.7% at 5 years Dutch cohort
Directional20Prophylactic contralateral mastectomy: 15-year survival 97.9% high-risk
Single sourceTreatment-Specific Survival Interpretation
While these numbers show an impressive menu of effective options, the overwhelming takeaway is that a diagnosis of DCIS, while serious, comes with a survival prognosis so favorable that the greatest challenge is often choosing the right treatment from an arsenal of excellent choices.